172 related articles for article (PubMed ID: 7327373)
1. Elimination of tumor-enhancing cells by cyclophosphamide and its relevance to cyclophosphamide therapy of the murine mammary tumor.
Nakajima H; Abe S; Masuko Y; Tsubouchi J; Yamazaki M; Mizuno D
Gan; 1981 Oct; 72(5):723-31. PubMed ID: 7327373
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of murine tumors with a degraded D-manno-D-glucan (DMG) from Microellobosporia grisea, and cyclophosphamide.
Nakajima H; Hashimoto S; Kita Y; Takashi T; Tsukada W; Kohno M; Ogawa H; Abe S; Mizuno D
Jpn J Exp Med; 1983 Dec; 53(6):263-9. PubMed ID: 6240552
[TBL] [Abstract][Full Text] [Related]
3. Effect of cyclophosphamide on spleen cell suppressor activity and tumour growth in mice.
Larsen FS; Spärck JV
Acta Pathol Microbiol Immunol Scand C; 1983 Oct; 91(5):323-33. PubMed ID: 6229132
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid.
Youn JK; Lacour F; Hue G
Cancer Res; 1982 Nov; 42(11):4706-11. PubMed ID: 7127305
[TBL] [Abstract][Full Text] [Related]
6. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
7. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
8. Changes of antitumor immunity of hosts with murine mammary tumors regressed by lentinan: potentiation of antitumor delayed hypersensitivity reaction.
Masuko Y; Nakajima H; Tsubouchi J; Yamazaki M; Mizuno D; Abe S
Gan; 1982 Oct; 73(5):790-7. PubMed ID: 7166231
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of antitumor immunity in tumor-bearing mice by a degraded D-manno-D-glucan (DMG), a new antitumor polysaccharide.
Nakajima H; Kita Y; Hashimoto S; Tsukada W; Abe S; Mizuno D
Jpn J Exp Med; 1983 Dec; 53(6):281-8. PubMed ID: 6680757
[TBL] [Abstract][Full Text] [Related]
10. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of in vivo and in vitro murine immune responses by the cyclophosphamide metabolite acrolein.
Kawabata TT; White KL
Cancer Res; 1988 Jan; 48(1):41-5. PubMed ID: 3257162
[TBL] [Abstract][Full Text] [Related]
12. Regulation of delayed-type hypersensitivity. III. Effect of cyclophosphamide on the suppressor cells for delayed-type hypersensitivity to sheep erythrocytes in mice.
Gill HK; Liew FY
Eur J Immunol; 1978 Mar; 8(3):172-6. PubMed ID: 306925
[TBL] [Abstract][Full Text] [Related]
13. Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide.
Tzai TS; Lin JS; Chow NH
J Surg Res; 1996 Oct; 65(2):139-44. PubMed ID: 8903460
[TBL] [Abstract][Full Text] [Related]
14. Correlation of antitumor chemoimmunotherapy with bone marrow macrophage precursor cell stimulation and macrophage cytotoxicity.
Fisher B; Wolmark N
Cancer Res; 1976 Jul; 36(7 PT 1):2241-7. PubMed ID: 1277129
[TBL] [Abstract][Full Text] [Related]
15. The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system.
Nishimura Y; Eto M; Maeda T; Hiromatsu K; Nomoto K; Kong YY; Nomoto K
Immunobiology; 1995 Aug; 193(5):420-38. PubMed ID: 8522358
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
Fisher B; Gebhardt M
Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
[TBL] [Abstract][Full Text] [Related]
17. Tolerance induction of alloreactivity by portal venous inoculation with allogeneic cells followed by the injection of cyclophosphamide. I. Specific suppression of alloreactive cytotoxic and delayed-type hypersensitivity responses as well as allograft rejection.
Qian JH; Kokudo S; Sato S; Hamaoka T; Fujiwara H
Transplantation; 1987 Apr; 43(4):538-43. PubMed ID: 3495052
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas.
Yu S; Lannin DR; Tsui-Collins AL; McKhann CF
Cancer Res; 1980 Aug; 40(8 Pt 1):2756-61. PubMed ID: 7388826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
